Tiagabine in clinical practice

Epilepsia

Volumn 42, Issue SUPPL. 3, 2001, Pages 42-45

  Genton, Pierre ^a,b   Guerrini, Renzo ^a,c   Perucca, Emilio ^a  

^a CENTRE SAINT PAUL   (France)

^b DEPARTMENT OF DEVELOPMENTAL NEUROSCIENCE   (Italy)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Focal epilepsy; Tiagabine

Indexed keywords

TIAGABINE;

CLINICAL TRIAL; CONFERENCE PAPER; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INDUCTION; FATIGUE; GASTROINTESTINAL ABSORPTION; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; TEMPORAL LOBE EPILEPSY; TREATMENT PLANNING; VERTIGO;

EID: 0034871560     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.2001.042suppl.3042.x     Document Type: Conference Paper

References (24)

1. Tiagabine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy
2. A review of the preclinical pharmacology of tiagabine, a potent and selective anticonvulsant GABA uptake inhibitor
3. Gabitril: Current aspects, future perspectives
4. Adjunctive treatment of partial seizures with tiagabine: A placebo-controlled trial
5. Tiagabine therapy for complex partial seizures: A dose-frequency study
6. Tiagabine for complex partial seizures: A randomized, add-on, dose-response trial
7. Safety of tiagabine HC1 monotherapy in the treatment of seizures: High dose versus low dose
8. Tiagabine monotherapy in the treatment for partial epilepsy
9. Efficacy of tiagabine in older pediatric patients with refractory partial seizures
10. Single-blind study of safety, tolerability, and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy
11. Long-term treatment of partial seizures with tiagabine in children
12. Use of tiagabine as long-term therapy for complex partial seizures in adolescents
13. Tiagabine: The safety landscape
14. Safety of tiagabine: Summary of 53 trials
15. Severe persistent visual field constriction associated with vigabatrin
16. Absence of concentric visual field defects in patients with long-term tiagabine monotherapy
17. Aggravation of seizures by antiepileptic drugs: What to do in clinical practice
18. Utility of the lethargic (lh/lh) mouse model of absence seizure in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures
19. Treatment of experimental status epilepticus with the GABA uptake inhibitor, tiagabine
20. Calcium-dependent regulation of genetically determined spike-and-waves by the reticular thalamic nucleus in the rat
21. Tiagabine-induced absence status in idiopathic generalized epilepsy
22. Two cases of non-convulsive status epilepticus in association with tiagabine therapy
23. Tiagabin und nonkonvulsiver status epilepticus
24. Hypothesis that tiagabine-induced NCSE is associated with GABAergic hyperfunction, with GABA(B) receptors playing a critical role, is supported by a case of generalized NCSE induced by baclofen